Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients with Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study - OSKIRA 4 SS

Study identifier:D4300C00004Sub

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Placebo or Adalimumab Monotherapy in Patients with Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study

Medical condition

Rheumatoid Arthritis

Phase

Phase 2

Healthy volunteers

No

Study drug

Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab

Sex

All

Actual Enrollment

198

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 Feb 2011
Primary Completion Date: 01 Jul 2013
Study Completion Date: 01 Jul 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria